Physician profile
Floyd E Phillips
NPI 1942297916
$12,330.49
in general payments reported to CMS, 2019-2025
52 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $938 · 2021: $2,324 · 2022: $1,786 · 2023: $2,053 · 2024: $2,111 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,559 · Education: $13.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.37 |
| Education | $13.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,974.63 | 2019-2025 | |
| Novo Nordisk INC | $1,683.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,384.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $766.52 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $662.10 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.29 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $540.20 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $421.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $412.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.91 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $341.89 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Novartis Pharmaceuticals Corporation | $244.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.53 | 2021-2025 | |
| Lilly USA, LLC | $222.55 | 2019-2023 | Lyumjev, Jardiance, Baqsimi |
| Amgen INC. | $210.31 | 2019-2024 | Repatha, Otezla |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.